Protecting Consumer Privacy in DTC Tissue Testing
The privatization of next-generation medical technologies, especially in regenerative and precision medicine, further muddies the data-protection waters.

Continued efforts to increase diversity in genetic research are needed.

The Journal of Law and the Biosciences ranks first in the legal medicine category, second in medical ethics, and third among ethics journals.

By Kayte Spector-Bagdady JD, MBioethics Department of Obstetrics & Gynecology; Research Ethics Service, Center for Bioethics & Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI With recent reports of Google’s data deals with Ascension health and the University of Chicago, there has been a lot of attention paid recently to the…

Persons with disabilities constitute the largest health disparities group in the U.S., but they have largely been absent from the conversations on precision medicine research.

By Mildred K. Cho, PhD In 2017, the US FDA approved a gene therapy for the first time. However, it’s important to remember that the term “gene therapy” has been an optimistic misnomer for nearly 30 years, since the first clinical trial of a gene-based intervention was initiated in 1990. Although the FDA has now…
By Leslie Francis Persistent differences in participation in clinical trials by race and ethnicity are well known; for example, the 2015 Report of the Working Group on Precision Medicine (PMI) relies on statistics that only 5% of clinical trial participants are African-American and only 1% are Hispanic. A recently-launched website of the FDA, “Drug Trials…